Drug Trial Radar · NCT07065331
A Study of Inhaled AZD8630 in Adolescents With Asthma
Last checked: Nov 19, 2026Latest source record: Oct 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Jun 11, 2025
Primary completion
Sep 19, 2025
Study completion Sep 19, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jul 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the pharmacokinetic (PK) profile, safety, tolerability, and immunogenicity of single inhaled dose of AZD8630 administered in adolescent participants with asthma as well as the safety and performance of the dry powder inhaler.
Conditions
- Asthma
Interventions
AZD8630Drug
Single inhaled dose of AZD8630 via dry powder inhaler.
Dry powder inhalerDevice
Single inhaled dose of AZD8630 via dry powder inhaler.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the serum concentration-time curve from time zero to 24 hours (AUC0-24)Time frame: Up to Day 9
- Maximum observed drug concentration (Cmax)Time frame: Up to Day 9
- Time to reach peak or maximum observed concentration (Tmax)Time frame: Up to Day 9
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Bakersfield, California
Research Site
Miami Lakes, Florida
Research Site
Lafayette, Louisiana
Research Site
Raleigh, North Carolina
Research Site
Toledo, Ohio
Research Site
Oklahoma City, Oklahoma
Research Site
Spartanburg, South Carolina
Research Site
Boerne, Texas
Research Site
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.